Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Total Liabilities
Everything the company owes to creditors and other parties.
Solid Biosciences Inc.NASDAQ: SLDB
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $48.76M at the end of Q1 FY2026, down 1.4% from a year earlier and down 7.2% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Total liabilities amounted to 11.5% of total assets at the end of Q1 FY2026, down 2.8 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -1.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 52.53M USD
- Year-over-year change
- +2.2%
- 4-year CAGR
- +21.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.53M | +2.2% |
| FY2024 | 2024-12-31 | 51.42M | +33.7% |
| FY2023 | 2023-12-31 | 38.46M | -20.8% |
| FY2022 | 2022-12-31 | 48.59M | +101.0% |
| FY2021 | 2021-12-31 | 24.17M | — |
Total Liabilities vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's Mar 2026 total liabilities of $48.76M is the 7th highest of the 10 companies compared; the peer median is $147.35M.
- Its year-over-year change of -1.4% is the 8th highest of 10, against a peer median of +32.7%.
- Total liabilities amounts to 11.5% of total assets for SLDB, versus a peer median of 14.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.42B | +20.2% | +14.8% | 105.1% | |
| Mar 2026 | $1.67B | -27.9% | -7.0% | 52.7% | |
| Mar 2026 | $302.79M | +58.6% | +7.7% | 123.8% | |
| Jun 2026 | $291.86M | +85.3% | +58.5% | 29.4% | |
| Sep 2026 | $147.35M | +493.7% | +14.2% | 8.3% | |
| Mar 2026 | $61.07M | +32.7% | +26.0% | 11.9% | |
| Mar 2026 | $48.76M | -1.4% | +2.6% | 11.5% | |
| Mar 2026 | $47.58M | +82.2% | +9.4% | 14.6% | |
| Mar 2026 | $25.36M | +7.9% | +30.6% | 9.6% | |
| Mar 2026 | $22.32M | -37.3% | -11.2% | 14.3% | |
| Peer median (excluding SLDB) | $147.35M | +32.7% | +14.2% | 14.6% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 119.14M | 155.38M | 74.02M | 80.24M | 59.9M |
| Short-term Investments | 88.64M | 58.34M | 49.63M | 68.69M | 127.95M |
| Net Receivables | 110K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.71M | 3M | 2.11M | 1.65M | 17.61M |
| Total Current Assets | 222.61M | 219.64M | 129.73M | 157.3M | 205.46M |
| Property, Plant & Equipment (Net) | 7.6M | 38.61M | 33.16M | 29.04M | 26.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.16M | 2.01M | 2.04M | 2.32M | 991K |
| Total Non-current Assets | 9.77M | 40.61M | 35.21M | 31.36M | 27.08M |
| Total Assets | 232.38M | 260.25M | 164.94M | 188.66M | 232.54M |
| Account Payables | 4.46M | 3.24M | 2.03M | 4.24M | 3.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.08M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.12M | 8.38M | 5.95M | 9.37M | 28.15M |
| Total Current Liabilities | 23.6M | 22.51M | 14.52M | 30.26M | 33.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 96K | 0 | 0 | 0 |
| Total Non-current Liabilities | 568K | 26.08M | 23.94M | 21.16M | 19.06M |
| Total Liabilities | 24.17M | 48.59M | 38.46M | 51.42M | 52.53M |
| Common Stock | 7K | 20K | 20K | 40K | 79K |
| Retained Earnings | (476.76M) | (562.74M) | (658.75M) | (783.45M) | (957.78M) |
| Accumulated OCI | (45K) | (68K) | 15K | 47K | 52K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M |
| Total Debt | 2.06M | 28.55M | 26.27M | 24.18M | 21.16M |
| Net Debt | (117.07M) | (126.84M) | (47.75M) | (56.06M) | (38.74M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.